First Clinical Site Announced for Phase 2 Trial Testing Levosimendan for PH Linked to Heart Disease
The Stanford University School of Medicine is the first clinical site for a Phase 2 trial testing levosimendan as a potential treatment for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), Tenax Therapeutics recently announced. Ejection fraction is the amount of blood that the…